Unicycive Therapeutics (UNCY) PT Lowered to $3 at Benchmark
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts UNCY Hot Sheet
Price: $4.19 -0.71%
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 20 | New: 35
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 20 | New: 35
Join SI Premium – FREE
Benchmark analyst Brice Jackson lowered the price target on Unicycive Therapeutics (NASDAQ: UNCY) to $3.00 (from $13.00) while maintaining a Speculative Buy rating.
You May Also Be Interested In
- Enovis Corp (ENOV) PT Lowered to $44 at UBS
- Incyte (INCY) PT Raised to $127 at UBS, Neutral Rating Maintained
- DTE Energy (DTE) PT Raised to $134 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
